GGrantIndex
← Leaderboards

Christie M Orschell

Indiana Univ-Purdue Univ At Indianapolis

$7,516,916
Attributed
$9,278,887
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $901.1K · FY200524
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$9,278,887 · 7

By mechanism

U01$5,609,893 · 2
R01$1,825,968 · 1
U19$1,159,032 · 1
UH3$450,000 · 1
UH2$149,622 · 1
S10$84,372 · 1

Top collaborators

Most similar at Indiana Univ-Purdue Univ At Indianapolis

Same institution · by research overlap

Others in their field

Top investigators on “Hematopoietic Stem Cells

Research focus

Hematopoietic Stem CellsHematopoieticRadiationHematopoiesisCessation Of LifeRecoveryTissuesBaseAnimal ModelElderlyAffectHematopoietic SystemFda ApprovedHemorrhageCsf3 GeneResponseNational Institute Of Allergy And Infectious DiseaseCellsBone MarrowProgramsAdultRadiation ToxicityGrantAnimals

Grant awards (26)

Development of dmPGE2 and Bcl-xl-targeting senolytics as medical countermeasures for H-ARS and DEARE$222,239
U19 · FY2024 · AI · contact PI
Development of dmPGE2 and Bcl-xl-targeting senolytics as medical countermeasures for H-ARS and DEARE$217,049
U19 · FY2023 · AI · contact PI
Extending the scope of PLX-R18 for H-ARS: efficacy in special populations and DEARE$502,589
U01 · FY2022 · AI · contact PI
Development of dmPGE2 and Bcl-xl-targeting senolytics as medical countermeasures for H-ARS and DEARE$230,093
U19 · FY2022 · AI · contact PI
Extending the scope of PLX-R18 for H-ARS: efficacy in special populations and DEARE$507,999
U01 · FY2021 · AI · contact PI
Development of dmPGE2 and Bcl-xl-targeting senolytics as medical countermeasures for H-ARS and DEARE$238,276
U19 · FY2021 · AI · contact PI
Extending the scope of PLX-R18 for H-ARS: efficacy in special populations and DEARE$518,282
U01 · FY2020 · AI · contact PI
Development of dmPGE2 and Bcl-xl-targeting senolytics as medical countermeasures for H-ARS and DEARE$251,375
U19 · FY2020 · AI · contact PI
Age-Related Differences in Response to Radiation and Medical Countermeasures$131,435
UH3 · FY2020 · AI · contact PI
Extending the scope of PLX-R18 for H-ARS: efficacy in special populations and DEARE$628,096
U01 · FY2019 · AI · contact PI
Age-Related Differences in Response to Radiation and Medical Countermeasures$148,496
UH3 · FY2019 · AI · contact PI
Extending the scope of PLX-R18 for H-ARS: efficacy in special populations and DEARE$528,607
U01 · FY2018 · AI · contact PI
Age-Related Differences in Response to Radiation and Medical Countermeasures$170,069
UH3 · FY2018 · AI · contact PI
Long-acting growth factors for treating the acute and long term effects of lethal$476,768
U01 · FY2017 · AI
Age-Related Differences in Response to Radiation and Medical Countermeasures$97,541
UH2 · FY2017 · AI · contact PI
Long-acting growth factors for treating the acute and long term effects of lethal$674,036
U01 · FY2016 · AI
Age-Related Differences in Response to Radiation and Medical Countermeasures$52,081
UH2 · FY2016 · AI · contact PI
Long-acting growth factors for treating the acute and long term effects of lethal$553,403
U01 · FY2015 · AI
Long-acting growth factors for treating the acute and long term effects of lethal$731,319
U01 · FY2014 · AI
Long-acting growth factors for treating the acute and long term effects of lethal$488,794
U01 · FY2013 · AI
BioPlex 200 System with High Throughput Fluidics (HTF) Multiplex Array System$84,372
S10 · FY2010 · RR · contact PI
Multifaceted Interventions to Amplify HSC Engraftment$359,123
R01 · FY2009 · HL · contact PI
Multifaceted Interventions to Amplify HSC Engraftment$359,123
R01 · FY2008 · HL · contact PI
Multifaceted Interventions to Amplify HSC Engraftment$359,123
R01 · FY2007 · HL · contact PI
Multifaceted Interventions to Amplify HSC Engraftment$369,849
R01 · FY2006 · HL · contact PI
Multifaceted Interventions to Amplify HSC Engraftment$378,750
R01 · FY2005 · HL